Newsfeeds Archive - Spark Newswire

1 minute read

Acasti Announces Poster Detailing GTX-104 STRIVE-ON Trial

February 1, 9:39 AM

The poster, Safety and Tolerability of Intravenous Versus Enteral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage, will be presented Thursday February 8th during the Ongoing Clinical Trials session of the

ACST

4 minute read

Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Avi Kapoor

January 18, 2:08 PM

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.

ACST

4 minute read

Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

September 26, 12:56 PM

Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome.

ACON

1 minute read

Why Acasti Pharma (ACST) Stock Is Exploding Higher

By Henry Khederian

September 26, 10:57 AM

Acasti Pharma Inc (NASDAQ: ACST) shares are trading higher by 34.3% to $2.35 Tuesday morning after the company announced $7.5 million in private placement equity financing.

ACST

2 minute read

Acasti To Present GTX-104 Pharmacokinetic Comparison Data At Neurocritical Care Annual Meeting

By Benzinga Newsdesk

August 9, 5:23 PM

Acasti Pharma Inc. (NASDAQ:ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104 its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease,

ACST

2 minute read

Acasti Pharma Announces 1-For-6 Reverse Stock Split

By Happy Mohamed

July 7, 8:03 AM

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a

ACST

4 minute read

Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

July 5, 1:28 PM

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in DRP-selected metastatic breast cancer patients.

ABL

1 minute read

Acasti Pharma Q3 EPS $(0.09) Beats $(0.11) Estimate, Cash Balance Of $31.3M With Cash Runway Into Q2 Of 2024

By Benzinga Newsdesk

February 14, 8:04 AM

Acasti Pharma (NASDAQ:ACST) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is unchanged from the same period last year.

ACST

8 minute read

Earnings

Earnings Scheduled For February 14, 2023

By Benzinga Insights

February 14, 5:44 AM

Companies Reporting Before The Bell • WESCO International (NYSE:WCC) is projected to report quarterly earnings at $3.79 per share on revenue of $5.37 billion.

ABNB

3 minute read

Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket

By Lisa Levin

January 6, 9:00 AM

Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products that address larger markets.

ABVC